Evid Invest
Holders — by stockHoldings — by fund

JOHNSON & JOHNSON

Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0000200406

$798.7M

disclosed book value

15

positions

37.6%

largest position share

Positions, as of 2026-06-30

top 15 of 15 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held

#IssuerSharesValue% of book
1PTGXPROTAGONIST THERAPEUTICS INC2.4M$300.2M37.6%
2NBTXNANOBIOTIX5.6M$212.0M26.5%
3MEIRAGTX HLDGS PLC6.6M$89.7M11.2%
4RAPPRAPPORT THERAPEUTICS INC1.8M$74.4M9.3%
5CTNMCONTINEUM THERAPEUTICS INC2.0M$32.4M4.1%
6LEGNLEGEND BIOTECH CORP814,586$23.5M2.9%
7CVRXCVRX INC4.0M$20.7M2.6%
8XNCRXENCOR INC748,062$12.0M1.5%
9CBRSCEREBRAS SYSTEMS INC53,586$11.8M1.5%
10FATEFATE THERAPEUTICS INC3.4M$9.1M1.1%
11PRCTPROCEPT BIOROBOTICS CORP357,939$8.1M1%
12NMRANEUMORA THERAPEUTICS INC.1.8M$3.1M0.4%
13VORVOR BIOPHARMA INC53,732$989,2060.1%
14LABSTANDARD BIOTOOLS INC311,967$256,6550%
15ACETADICET BIO INC22,779$196,8110%

Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.

EvidInvest is an independent research and information tool. Figures are calculated from public SEC filings and third-party market data and are provided for informational and educational purposes only. EvidInvest does not provide investment advice, brokerage, or financial services, and is not affiliated with any company it covers. Verify all figures against primary sources before making any decision.